This Week in Oncology — Jul 22, 2026

Editor's Pick: Tumor infiltrating lymphocytes as a predictor of adjuvant avelumab efficacy in patients with high-risk triple negative breast cancer (Clinical Cancer Research, 2026)
Welcome to This Week in Oncology. This week we're covering 5 notable papers spanning biomarker-driven immunotherapy, cellular therapy in gastrointestinal malignancy, antibody-drug conjugate mechanisms, and management of opportunistic fungal infections in oncology. Let's dive in.
This week's papers:
• Tumor infiltrating lymphocytes as a predictor of adjuvant avelumab efficacy in patients with high-risk triple negative breast cancer. — Clinical Cancer Research 2026 (pubmed.ncbi.nlm.nih.gov/42467210)
• Molecular Profiling of Tisotumab Vedotin-Treated Patients Identifies Immune Pathways Associated With Clinical Activity. — Clinical Cancer Research 2026 (pubmed.ncbi.nlm.nih.gov/42467245)
• Non-Armored GCC-targeting CAR-T cell therapy demonstrates significant efficacy in patients with advanced colorectal cancer. — Clinical Cancer Research 2026 (pubmed.ncbi.nlm.nih.gov/42467218)
• Olorofim in Treatment of Patients With Poorly Controlled Disseminated Coccidioidomycosis : A Single-Group, Open-Label, Phase 2b, Multicenter Study. — Annals of Internal Medicine 2026 (pubmed.ncbi.nlm.nih.gov/42475691)
Listen at AudioScholar (audioscholar.cc/episode/xbnb6mhawz)